Lupin arm unveils Luforbec 100/6 for adult asthma, COPD treatment in Germany

Mumbai: Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec 100/6 (beclometasone 100 µg / formoterol 6 µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Luforbec 100µg/6µg pMDI is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is suitable. With the same active ingredients as Foster 100/6 pMDI and an extra fine formulation, Luforbec offers the same licensed indications and similar device characteristics. Luforbec pMDI provide significant cost savings, priced at - 47% below the fixed reference price on the pharmacy selling price.

"With a significant portion of the population (5% of adults and 10% of children) currently undergoing asthma treatment, Luforbec 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals. This launch reflects Lupin’s unwavering commitment to addressing the critical needs of asthma management in Germany," the company stated in a recent release.

Anjan Selz, Managing Director, Hormosan Pharma GmbH, added, "The launch of Luforbec 100/6 pMDI in Germany represents a significant milestone in our goal to establish Hormosan as a key player in the inhalation segment. We are committed to improving healthcare outcomes by ensuring the accessibility and affordability of reliable and comprehensive solutions for patients and healthcare professionals. This launch reinforces our dedication to making asthma and COPD management more accessible for the German population

Read also: Lupin bags USFDA nod for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.